Clinical Trial Update: iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV) [Phase 1]

View source ↗

Summary

Phase 1 trial of iSONEP for treating persistent pigment epithelial detachment in exudative age-related macular degeneration or polypoidal choroidal vasculopathy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• iSONEP (Sonepcizumab)

Snippet

Sponsor: Lpath, Inc. | Conditions: Pigment Epithelial Detachment | Phase 1 | Status: TERMINATED